NCT05122546View on ClinicalTrials.gov

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

October 25, 2025

Study Completion Date

October 25, 2025

Conditions
Advanced Clear Cell Renal Cell CarcinomaAdvanced Papillary Renal Cell CarcinomaAdvanced Renal Cell CarcinomaAdvanced Sarcomatoid Renal Cell CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMetastatic Papillary Renal Cell CarcinomaMetastatic Renal Cell CarcinomaMetastatic Sarcomatoid Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Unresectable Clear Cell Renal Cell CarcinomaUnresectable Renal Cell Carcinoma
Interventions
DRUG

Cabozantinib S-malate

Given PO

DRUG

Clostridium butyricum CBM 588 Probiotic Strain

Given PO

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER